Population pharmacokinetics of ramipril in patients with chronic heart failure: A real-world longitudinal study

1 S. Stewart, I. Ekman, T. Ekman, A. Oden and A. Rosengren, Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004), Circ. Cardiovasc. Qual. Outcomes 3(6) (2010) 573–580; https://doi.org/10.1161/CIRCOUTCOMES.110.957571 Search in Google Scholar

2 T. A. McDonagh, M. Metra, M. Adamo, R. S. Gardner, A. Baumbach, M. Böhm, H. Burri, J. Butler, J. Čelutkienė, O. Chioncel, J. G. F. Cleland, A. J. S. Coats, M. G. Crespo-Leiro, D. Farmakis, M. Gi-lard, S. Heymans, A. W. Hoes, T. Jaarsma, E. A. Jankowska and A. K. Skibelund, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur. Heart J. 42(36) (2021) 3599–3726; https://doi.org/10.1093/eurheartj/ehab368 Search in Google Scholar

3 E. Lonn, Dose response of ACE inhibitors: implications of the SECURE trial, Trials 2(4) (2001) 155–159; https://doi.org/10.1186/cvm-2-4-155 Search in Google Scholar

4 D. S. Roffman, High-versus low-dose ACE inhibitor therapy in chronic heart failure. Ann. Pharmacother. 38(5) (2004) 831–838; https://doi.org/10.1345/aph.1C402 Search in Google Scholar

5 E. R. Debusmann, J. O. Pujadas, W. Lahn, R. Irmisch, F. Jane, T. S. Kuan, J. Mora, U. Walter, H. G. Eckert, P. Hajdu and H. Metzger, Influence of renal function on the pharmacokinetics of ramipril (HOE 498), Am. J. Cardiol. 59(10) (1987) 70D–78D; https://doi.org/10.1016/0002-9149(87)90057-9 Search in Google Scholar

6 J. M. van Griensven, R. C. Schoemaker, A. F. Cohen, H. G. Luus, M. Seibert-Grafe and H. J. Rothig, Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril, Eur. J. Clin. Pharmacol. 47(6) (1995) 513–518. https://doi.org/10.1007/BF00193704 Search in Google Scholar

7 D. G. Levitt and R. C. Schoemaker, Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat, BMC Clin. Pharmacol. 6(1) (2006); https://doi.org/10.1186/1472-6904-6-1 Search in Google Scholar

8 B. Beermann, O. Nyquist, C. Hoglund, K. A. Jacobsson, U. Naslund and M. Jensen-Urstad, Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study, Eur. J. Clin. Pharmacol 45(3) (1993) 241–246; https://doi.org/10.1007/BF00315390 Search in Google Scholar

9 H. Schunkert, J. Kindler, M. Gassmann, W. Lahn, R. Irmisch, E. Ritz, E. R. Debusmann, J. O. Puja das, K. M. Koch and H. G. Sieberth, Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency, Eur. J. Clin. Pharmacol. 37(3) (1989) 249–256; https://doi.org/10.1007/BF00679779 Search in Google Scholar

10 M. Verho, C. Luck, W. J. Stelter, B. Rangoonwala and N. Bender, Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man, Curr. Med. Res. Opin. 13(5) (1995) 264–273; https://doi.org/10.1185/03007999509111551 Search in Google Scholar

11 U. Gerckens, E. Grube, T. Mengden, H. Sigel, W. L. Wagner, T. Lahn, R. Irmisch and H. Metzger, Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV), J. Cardiovasc. Pharmacol. 13 Suppl 3 (1989) S49–51; https://doi.org/10.1097/00005344-198900133-00012 Search in Google Scholar

12 B. Heintz, M. Verho, D. Brockmeier, G. Luckel, S. Maigatter, H. G. Sieberth, B. Rangoonwala and N. Bender, Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure, J. Cardiovasc. Pharmacol. 22 Suppl 9 (1993) S36–42. Search in Google Scholar

13 G. Loncar, J. Springer, M. Anker, W. Doehner and M. Lainscak, Cardiac cachexia: hic et nunc, J. Cachexia Sarcopenia Muscle 7(3) (2016) 246–60; https://doi.org/10.1002/jcsm.12118 Search in Google Scholar

14 S. Khan and A. Shahzadi, Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review, Drug Metab. Rev. 51(1) (2019) 1–11. https://doi.org/10.1080/03602532.2018.1508226 Search in Google Scholar

15 K. Trobec, M. Kerec Kos, S. von Haehling, J. Springer, S. D. Anker and M. Lainscak, Pharmacokinetics of drugs in cachectic patients: a systematic review, PLoS One 8(11) (2013) e79603 (10 pages); https://doi.org/10.1371/journal.pone.0079603 Search in Google Scholar

16 S. Janmahasatian, S. B. Duffull, S. Ash, L. C. Ward, N. M. Byrne and B. Green, Quantification of lean bodyweight, Clin. Pharmacokinet. 44(10) (2005) 1051–1065; https://doi.org/10.2165/00003088-200544100-00004 Search in Google Scholar

17 L. I. Cortinez, B. J. Anderson, N. H. Holford, V. Puga, N. de la Fuente, H. Auad, S. Solari, F. A. Allende and M. Ibacache, Dexmedetomidine pharmacokinetics in the obese. Eur. J. Clin. Pharmacol. 71(12) (2015) 1501–1508; https://doi.org/10.1007/s00228-015-1948-2 Search in Google Scholar

18 I. Janssen, R. N. Baumgartner, R. Ross, I. H. Rosenberg and R. Roubenoff, Skeletal muscle cut-points associated with elevated physical disability risk in older men and women, Am. J. Epidemiol. 159(4) (2004) 413–421; https://doi.org/10.1093/aje/kwh058 Search in Google Scholar

19 I. Janssen, S. B. Heymsfield, R. N. Baumgartner and R. Ross, Estimation of skeletal muscle mass by bioelectrical impedance analysis, J. Appl. Physiol. 89(2) (2000) 465–471; https://doi.org/10.1152/jappl.2000.89.2.465 Search in Google Scholar

20 O. González, M. E. Blanco, G. Iriarte, L. Bartolomé, M. I. Maguregui and R. M. Alonso, Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect, J. Chromatogr. A 1353 (2014) 10–27; https://doi.org/10.1016/j.chroma.2014.03.077 Search in Google Scholar

21 C. Ghosh, Relative matrix effects: A step forward using standard line slopes and ANOVA analysis, Arab. J. Chem. 12(7) (2019) 1378–1386; https://doi.org/10.1016/j.arabjc.2014.11.019 Search in Google Scholar

22 A. M. Alvarez and D. Mukherjee, Liver abnormalities in cardiac diseases and heart failure, Int. J. Angiol. 20(3) (2011)135–142; https://doi.org/10.1055/s-0031-1284434 Search in Google Scholar

23 M. D. Samsky, C. B. Patel, T. A. DeWald, A. D. Smith, G. M. Felker, J. G. Rogers and A. F. Hernandez, Cardiohepatic interactions in heart failure: an overview and clinical implications, J. Am. Coll. Cardiol. 61(24) (2013) 2397–2405; https://doi.org/10.1016/j.jacc.2013.03.042 Search in Google Scholar

24 T. Narumi, T. Watanabe, S. Kadowaki, T. Takahashi, M. Yokoyama, D. Kinoshita, Y. Honda, A. Funayama, S. Nishiyama, H. Takahashi, T. Arimoto, T. Shishido, T. Miyamoto and I. Kubota, Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure, Eur. J. Intern. Med. 26(2) (2015) 118–122; https://doi.org/10.1016/j.ejim.2015.01.008 Search in Google Scholar

25 N. H. Uszko-Lencer, F. Bothmer, P. E. van Pol and A. M. Schols, Measuring body composition in chronic heart failure: a comparison of methods, Eur. J. Heart Fail 8(2) (2006) 208–214; https://doi.org/10.1016/j.ejheart.2005.07.007 Search in Google Scholar

26 P. L. Toutain and H. P. Lefebvre, Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors, J. Vet. Pharmacol. Ther. 27(6) (2004) 515–525; https://doi.org/10.1111/j.1365-2885.2004.00601.x Search in Google Scholar

27 R. Thomsen, H. B. Rasmussen, K. Linnet and INDICES Consortium, In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors, Drug Metab. Dispos. 42(1) (2014) 126–133; https://doi.org/10.1124/dmd.113.053512 Search in Google Scholar

28 W. J. Gilchrist, K. Beard, P. Manhem, E. M. Thomas, J. I. Robertson and S. G. Ball, Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients, Am. J. Cardiol. 59(10) (1987) 28D–32D; https://doi.org/10.1016/0002-9149(87)90049-X Search in Google Scholar

29 R. Ogawa, J. M. Stachnik and H. Echizen, Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally), Clin. Pharmacokinet. 53(12) (2014) 1083–1114; https://doi.org/10.1007/s40262-014-0189-3 Search in Google Scholar